secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001125345-23-000077
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics reports Q1 net loss $38M; cash runway through 2025 on $270M non-dilutive funding
--------------------------------------------------------------------------------

- Net loss of $38.0M ($0.61 loss per share) vs. $66.4M loss year ago; revenue $24.5M (up 121% YoY).
- Cash, equivalents & marketable securities $241.7M at March 31, 2023; additional $30M approval milestone from TZIELD received after Q1.
- ZYNYZ (retifanlimab) approved by FDA for MCC; MacroGenics received $15M milestone, eligible for up to $650M more plus tiered royalties.
- Sold TZIELD royalty interest to DRI for $100M upfront; retains 50% share above threshold and up to $430M in Sanofi milestones.
- Phase 2 TAMARACK (vobra duo in mCRPC) enrollment under revised protocol to start Q2 2023; clinical update expected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000077/0001125345-23-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000077/mgnx-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001125345-23-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer